Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Lai X.,,Computational analysis of target hub gene repression regulated by multiple and cooperative miRNAs,2012,Nucleic Acids Research,53,10.1093/nar/gks657,Germany,Article,Rostock,1,Journal,2-s2.0-84867499417
Alla V.,,E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry,2012,Cell Cycle,71,10.4161/cc.21476,Germany,Article,Rostock,1,Journal,2-s2.0-84865344231
Marin J.J.G.,,Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs,2012,Current Cancer Drug Targets,49,10.2174/156800912800190875,Spain;Spain,Review,Madrid;Salamanca,0,Journal,2-s2.0-84860282454
Engelmann D.,,The dark side of E2F1: In transit beyond apoptosis,2012,Cancer Research,100,10.1158/0008-5472.CAN-11-2575,Germany,Review,Rostock,1,Journal,2-s2.0-84856557109
Bryant J.L.,,A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT,2012,British Journal of Cancer,75,10.1038/bjc.2011.465,United States,Article,Lexington,1,Journal,2-s2.0-84855359334
Li Y.,,Microrna-mediated positive feedback loop and optimized bistable switch in a cancer network involving miR-17-92,2011,PLoS ONE,33,10.1371/journal.pone.0026302,China;China,Article,Lanzhou;Lanzhou,1,Journal,2-s2.0-80054711591
Rosanò L.,,Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells,2011,Clinical Cancer Research,133,10.1158/1078-0432.CCR-10-2325,Italy,Article,Roma,1,Journal,2-s2.0-79954627096
Garrett J.T.,,Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase,2011,Proceedings of the National Academy of Sciences of the United States of America,294,10.1073/pnas.1016140108,United States,Article,Nashville,1,Journal,2-s2.0-79953207364
Wiklund E.D.,,Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer,2011,International Journal of Cancer,296,10.1002/ijc.25461,Denmark;Australia,Article,Aarhus;Sydney,1,Journal,2-s2.0-79551469293
Wong J.,,Viral-Mediated Noisy Gene Expression Reveals Biphasic E2f1 Response to MYC,2011,Molecular Cell,37,10.1016/j.molcel.2011.01.014,United States,Article,Durham,1,Journal,2-s2.0-79251573545
Zhu S.,,DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib,2011,Gastroenterology,25,10.1053/j.gastro.2011.06.070,United States,Article,Nashville,0,Journal,2-s2.0-80054861063
Chang A.,,"Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC",2011,Lung Cancer,270,10.1016/j.lungcan.2010.08.022,Singapore,Review,Singapore City,0,Journal,2-s2.0-78650236850
Vera J.,,Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models,2010,Molecular BioSystems,16,10.1039/c0mb00018c,Germany,Article,Rostock,0,Journal,2-s2.0-77957928119
Zhang X.P.,,Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage,2010,Journal of Biological Chemistry,34,10.1074/jbc.M110.134650,China,Article,Nanjing,1,Journal,2-s2.0-77957767333
Engelmann D.,,Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance,2010,Drug Resistance Updates,49,10.1016/j.drup.2010.06.001,Germany,Article,Rostock,0,Journal,2-s2.0-77957931294
Chung J.,,Targeting the p53-family in cancer and chemosensitivity: Triple threat,2010,Current Drug Targets,18,10.2174/138945010791170833,Canada;Canada,Article,Toronto;Toronto,0,Journal,2-s2.0-77953497421
Engelmann D.,,Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death,2010,Cellular and Molecular Life Sciences,22,10.1007/s00018-009-0222-0,Germany,Article,Rostock,0,Journal,2-s2.0-77949529981
Alla V.,,E2F1 in melanoma progression and metastasis,2010,Journal of the National Cancer Institute,80,10.1093/jnci/djp458,Germany,Article,Rostock,1,Journal,2-s2.0-75149120225
Samavarchi-Tehrani P.,,Functional genomics reveals a BMP-Driven mesenchymal-to-Epithelial transition in the initiation of somatic cell reprogramming,2010,Cell Stem Cell,711,10.1016/j.stem.2010.04.015,Canada;Canada,Article,Toronto;Toronto,1,Journal,2-s2.0-77956320116
Gatenby R.,,Lessons from applied ecology: Cancer control using an evolutionary double bind,2009,Cancer Research,76,10.1158/0008-5472.CAN-09-1354,United States,Short Survey,Tampa,1,Journal,2-s2.0-70350236539
Polager S.,,P53 and E2f: Partners in life and death,2009,Nature Reviews Cancer,359,10.1038/nrc2718,Israel,Review,Ramat Gan,0,Journal,2-s2.0-70349437076
Emmrich S.,,Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo,2009,Molecular Cancer,46,10.1186/1476-4598-8-61,Germany,Article,Rostock,1,Journal,2-s2.0-69849096670
Wu H.,,Suppression of cell growth and invasion by miR-205 in breast cancer,2009,Cell Research,274,10.1038/cr.2009.18,United States,Article,IL,1,Journal,2-s2.0-64149089915
Gandellini P.,,MiR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cε,2009,Cancer Research,295,10.1158/0008-5472.CAN-08-2894,Italy,Article,Milan,1,Journal,2-s2.0-65549115615
Frogne T.,,"Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant",2009,Breast Cancer Research and Treatment,113,10.1007/s10549-008-0011-8,Denmark,Article,Copenhagen,0,Journal,2-s2.0-59449093537
Castillo J.,,Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform ΔEx2p73 in Human Hepatocellular Tumors,2009,Gastroenterology,57,10.1053/j.gastro.2009.07.065,Spain,Article,Pamplona,0,Journal,2-s2.0-70350122931
Aguda B.,,"MicroRNA regulation of a cancer network: Consequences of the feedback loops involving miR-17-92, E2F, and Myc",2008,Proceedings of the National Academy of Sciences of the United States of America,297,10.1073/pnas.0811166106,United States,Article,Columbus,1,Journal,2-s2.0-58149382580
Katoh Y.,,"Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review)",2008,International Journal of Molecular Medicine,197,10.3892/ijmm_00000019,Japan,Review,Tokyo,1,Journal,2-s2.0-53049097596
Yao G.,,A bistable Rb-E2F switch underlies the restriction point,2008,Nature Cell Biology,245,10.1038/ncb1711,United States;United States,Article,Durham;Durham,0,Journal,2-s2.0-43149108161
Massagué J.,,TGFβ in Cancer,2008,Cell,2530,10.1016/j.cell.2008.07.001,United States,Review,New York,1,Journal,2-s2.0-47549090432
Buhlmann S.,,DNp73 a matter of cancer: Mechanisms and clinical implications,2008,Biochimica et Biophysica Acta - Reviews on Cancer,46,10.1016/j.bbcan.2008.01.002,Germany,Review,Rostock,0,Journal,2-s2.0-41949088521
Vera J.,,Chapter 17 A System Biology Approach to Understand Functional Activity of Cell Communication Systems,2008,Methods in Cell Biology,24,10.1016/S0091-679X(08)00817-0,Germany,Review,Rostock,0,Book Series,2-s2.0-59049094552
Lee J.,,Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy,2008,Clinical Cancer Research,33,10.1158/1078-0432.CCR-07-0612,South Korea,Article,Suwon,1,Journal,2-s2.0-40949165837
Frolov A.,,ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib,2007,Cancer Biology and Therapy,71,10.4161/cbt.6.4.3849,United States,Article,Birmingham,1,Journal,2-s2.0-34548251394
Merlo L.,,Cancer as an evolutionary and ecological process,2006,Nature Reviews Cancer,1002,10.1038/nrc2013,United States,Review,Philadelphia,0,Journal,2-s2.0-33845243362
Stanelle J.,,E2F1-induced apoptosis: turning killers into therapeutics,2006,Trends in Molecular Medicine,89,10.1016/j.molmed.2006.02.002,Germany,Review,Rostock,0,Journal,2-s2.0-33646047403
Iwasa Y.,,Evolution of resistance during clonal expansion,2006,Genetics,151,10.1534/genetics.105.049791,Japan,Article,Fukuoka,1,Journal,2-s2.0-33646183071
Guan M.,,Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score,2005,Journal of Clinical Pathology,31,10.1136/jcp.2005.026955,China,Article,Shanghai,1,Journal,2-s2.0-27644458185
Melino G.,,p75 Induces Apoptosis via PUMA Transactivation and Bax Mitochondrial Translocation,2004,Journal of Biological Chemistry,289,10.1074/jbc.M307469200,United Kingdom;Italy,Article,Leicester;Rome,1,Journal,2-s2.0-1542379662
Tuve S.,,Alterations of ΔTA-p73 splice transcripts during melanoma development and progression,2004,International Journal of Cancer,47,10.1002/ijc.11552,Germany,Article,Essen,1,Journal,2-s2.0-0345256343
Han S.,,"E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide",2003,Breast Cancer Research and Treatment,55,10.1023/B:BREA.0000003843.53726.63,South Korea,Conference Paper,Seoul,0,Journal,2-s2.0-0344394363
Mangan S.,,Structure and function of the feed-forward loop network motif,2003,Proceedings of the National Academy of Sciences of the United States of America,1133,10.1073/pnas.2133841100,Israel,Article,Rehovot,1,Journal,2-s2.0-0142027814
Pützer B.,,"Increased ΔN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived ΔN′-p73 transcript [2]",2003,Cell Death and Differentiation,39,10.1038/sj.cdd.4401205,Germany,Letter,Essen,1,Journal,2-s2.0-0038751809
González-García I.,,Metapopulation dynamics and spatial heterogeneity in cancer,2002,Proceedings of the National Academy of Sciences of the United States of America,129,10.1073/pnas.202139299,United States,Article,New Haven,1,Journal,2-s2.0-0036792092
Stiewe T.,,Transactivation-deficient δTA-p73 acts as an oncogene,2002,Cancer Research,166,,Germany,Article,Essen,0,Journal,2-s2.0-0036628511
Nakagawa T.,,Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter,2002,Molecular and Cellular Biology,166,10.1128/MCB.22.8.2575-2585.2002,Japan,Article,Chuo-ku,1,Journal,2-s2.0-0036203514
Rödicker F.,,Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction,2001,Cancer Research,42,,Germany,Article,Essen,0,Journal,2-s2.0-0035477398
Stiewe T.,,Role of the p53-homologue p73 in E2F1-induced apoptosis,2000,Nature Genetics,295,10.1038/82617,Germany,Article,Essen,0,Journal,2-s2.0-0033666776
Blattner C.,,Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53,1999,Molecular and Cellular Biology,194,10.1128/MCB.19.5.3704,United Kingdom,Article,Dundee,1,Journal,2-s2.0-0032939925
Inohara N.,,"Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L)",1997,EMBO Journal,308,10.1093/emboj/16.7.1686,United States,Article,Ann Arbor,0,Journal,2-s2.0-0030970085
